WHO ICTRP trial
Secukinumab Open Label Roll-over Extension Protocol
CTRI/2021/12/038694 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2021/12/038694 |
|---|---|
| Public title | Secukinumab Open Label Roll-over Extension Protocol |
| Scientific title | An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment |
| Primary sponsor | Novartis Healthcare Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Egypt;France;Greece;Guatemala;India;Malaysia;Mexico;Norway;Poland;Republic of Korea;Russian Federation;South Africa;Spain;Sweden;United States of… |
| Conditions | Health Condition 1: M148- Arthropathies in other specified diseases classified elsewhere |
| Interventions | Intervention1: Secukinumab: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFS) for s.c. injection, once every 4 weeks for 2 years. Control Intervention1: Not Applicable: Not Applicable |
| Registration date | Dec 16, 2021 |
| Target size | 646 |
| Secondary IDs | 2020-004284-98;CAIN457A02001B Version 00 Dated 23 Sep 2020;NCT04638647 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: